# Metformin Hydrochloride Sustained-release Tablets (Ⅲ) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease

> **NCT06932874** · PHASE4 · RECRUITING · sponsor: **China National Center for Cardiovascular Diseases** · enrollment: 356 (estimated)

## Conditions studied

- Atherosclerotic Heart Disease
- Type 2 Diabetes

## Interventions

- **DRUG:** Glucophage (Metformin Hydrochloride Tablets)
- **DRUG:** New sustained-release metformin tablets (Ⅲ)

## Key facts

- **NCT ID:** NCT06932874
- **Lead sponsor:** China National Center for Cardiovascular Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-04
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 356 (ESTIMATED)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06932874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06932874, "Metformin Hydrochloride Sustained-release Tablets (Ⅲ) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06932874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*